Technology ID
TAB-4917
Advancements in Hematopoietic Stem Cell Transplantation: Non-Toxic Conditioning with CD117-Targeted Monoclonal Antibodies
E-Numbers
E-102-2018-0
Lead Inventor
Rossi, Derrick
Lead IC
NIAID
Co-Inventors
Czechowicz, Agnieszka
Murphy, Philip
Li, Zhanzhuo
ICs
NIAID
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Rare/Neglected Diseases
Oncology
Immunology
Development Stages
Pre-clinical (in vivo)
Research Products
Human Cell Lines
Antibodies
The technology revolves around an innovative monoclonal antibody-based conditioning regimen for enhancing the engraftment of hematopoietic stem cells during bone marrow transplants. It features a novel antibody-drug conjugate that targets CD117, a marker on stem cells, to enable effective transplantation without the harmful side effects of traditional conditioning methods. This approach has shown remarkable success in pre-clinical in vivo studies, offering a significant leap forward in transplant medicine with its potential to facilitate safe, non-toxic, and universally applicable bone marrow transplants.
Commercial Applications
The CD117 antibody-drug conjugate technology holds promise for a wide array of applications including safer bone marrow transplants across mismatched donors, gene therapies requiring hematopoietic stem cell vectors, and potentially, treatments for a range of hematologic conditions. Its ability to facilitate engraftment without traditional conditioning could revolutionize the therapeutic landscape for patients requiring stem cell transplantation.
Competitive Advantages
The CD117 antibody-drug conjugate technology offers a non-toxic, highly effective alternative for bone marrow transplant conditioning. It achieves robust, long-term engraftment, reducing the need for chronic immunosuppression. Its effectiveness in both syngeneic and allogeneic settings enhances its versatility. This positions it as a leading candidate for transforming current transplant protocols and improving patient care.
Licensing Contact: